Reviewer #2 (Remarks to the Author):
In this manuscript the authors combine experimental evolution and theoretical modelling to study how bacterial populations adapt to fluctuating environments. In particular, this study focuses on evaluating the efficacy of sequential treatments to control resistance adaptation, a strategy that alternates between different antibiotics with the aim of reducing the overall fitness of the population by producing evolutionary mismatches. The main result of this study is that certain combinations of antibiotics can reverse multidrug resistance. This is a potentially interesting observation that could, in principle, help in the design of rational drug usage strategies to fight clinically relevant pathogens. However, this observation has been previously reported using different bacteria and drug combinations and therefore, although methodologically sound, I believe this study is not conceptually novel. Indeed, in the last couple of years a series of published papers have demonstrated, both theoretical ly and experimentally, that drug resistance can be controlled by appropriately cycling between different antibiotics, even in stringent scenarios where the drugs used are structurally similar (10.1371/journal.pone.0122283, 10.1371/journal.pcbi.1004493) or select for cross resistance (10.1371/journal.pbio.1002104). None of these papers has been cited in this manuscript.
The continuous culture device constructed by the authors is very interesting, as it allows implementation of feedback controllers that dynamically manipulate the environmental conditions from real-time estimates of bacterial density. Previous studies have focused on implementing serial dilution protocols with daily transfers, and therefore imposing a temporal structure characterised by growth-dilution cycles, but also limiting the switching rate to periods longer than one day. Surprisingly, despite the possibilities offered by their experimental system, the authors choose to implement periodic cycles with daily switches because "shorter intervals tended to delay the development of the antibiotic resistance" (page 5). This is a strange reason to ignore rapid switching rates, in particular given that the main goal of the study is "to suppress the development of drug resistant mutants" (page 2).
The mathematical model posed by the authors is based on positive autoregulation and double negative feedback loops that seems to be in agreement with the experimental data ( Figure 2 ). There are some cases where the data and the model produce different re sults (which is expected in a simple, phenomenological model) and the possible sources of disagreement are discussed in the Supplementary Material (Supp. Fig. 6a and Fig 3a) . I would suggest this discussion should be included in the main text. An important assumption of the theoretical model is the existence of a fitness cost associated with resistance, considered by imposing the constraint that "the resistance level eventually saturates" (page 6). I understand that this is a parsimonious modelling assumption, although (as the authors mention) some drug resistance mutations are essentially cost-free and, even if they are costly, the cost can be readily compensated. In any case, an immediate consequence of this assumption is that a multidrug resistant subpopulation would present a lower fitness than single-drug resistant strain in single-drug environments, and therefore it's not surprising that multidrug resistance can be reversed when only one antibiotic is deployed. Actually, it has already been shown mathematically that in a 2-locus, 2-allele model of a continuous culture device where drug-resistance is costly, that a multidrug resistant subpopulation can be minimised by appropriately cycling antibiotics, even when the drugs used interact synergistically (10.1098/rsif.2012.0279) .
I have serious concerns about the sample preparation used for the single -clone profiling and whole-genome sequencing. The authors describe in their methods (page 16) that evolved strains were diluted in LB with no drug and grown overnight before DNA extraction and performing MIC assays. I understand the need for greater densities in order to obtain large DNA quantities necessary for Illumina MiSeq sequencing, but removing the selective pressure in favour of resistant mutants could have significant consequences on the MIC of the evolved population, as well as in the mutations identified from genome sequencing. This step is critical in particular when, as argued by the authors, drug -resistance mutations are associated with a fitness cost (see, for example, 10.1093/gbe/evu106).
My main concern about this manuscript, however, is that the authors ignore a considerable body of literature relevant to the antibiotic cycling problem and yet they state in the introduction that "systematic investigations into how a bacterial population develops resistance to multiple cycling antibiotics have yet to be done". Indeed, this is a very difficult problem and one that needs more attention from scientific and medical communities and, although I think this study could be a contribution in the search for rational antibiotic deployment strategies, I also believe its imperative that the authors put their findings in the context of previously published studies.
Reviewer #3 (Remarks to the Author):
Yoshida and coworkers performed an extensive study in which they experimentally and theoretically elucidated how different temporal antibiotic dosing schemes affect the development of antibiotic resistance in E. coli. Motivated by recent experimental studi es, they constructed a continuous-culture device, which enabled them to dynamically adjust drug concentrations both on short time scales (to ensure constant selection pressure) and on longer time scales (to switch between different antibiotics). This custo m-built device that is similar to the "morbidostat" (Toprak et al., Nature Genetics, 2012) provides experimental flexibility and is well suited for assessing how the duration of antibiotic treatment prevents or promotes resistance evolution to sequential antibiotic treatments. The authors demonstrated that temporal cycling of drugs promotes genotypic and phenotypic heterogeneity, which is at the heart of resistance reversal. Their findings are supported by genotyping of bacterial populations and by a phenomenological model of resistance evolution in a multidrug environment.
The experimental part of the study appears largely well done with clearly described methods (where these deviate from reported ones). Careful experimental and theoretical studies are needed to understand and combat antibiotic resistance evolution; hence, this study will likely be interesting for a broad readership. The generated dataset is quite comprehensive and will represent a good reference for further studies of antibiotic resistance evolution. However, I have several concerns (see below) that need to be clarified to corroborate the proposed claims and increase confidence in the reliability of the data.
Major points: 1. The result that absolutely no resistance to one of the drug s evolves e.g. when KAN and POL or CHL and POL are switched would be quite striking but needs additional clarification. For one, conceptually similar experiments (using different drugs) were reported in the cited reference (Kim et al., PNAS, 2014) but this study consistently found increases in resistance to both drugs (as one would generally expect). What causes this difference? Some plausible explanation for this would be important. Also, the data in Fig. 1c ,e that show these results have features that require some explanation: in panel c, POL resistance increases by ~2-fold on day 10 but then decreases again on day 11 even though POL is present at that time. It would help to explain how that can happen because this selection against these first resistant mutants in the presence of the drug may be important for the observed phenomenon. In panel e, CHL resistance seems to start increasing right for the last data point on day 24. Overall, it would greatly help to explain the plausibility of these results in th e framework of basic population genetics (see below).
2. The theoretical model described in the Supplement contains parameters that are closely related to the parameters of the logistic equation used to quantify the abruptness of the antibiotic resistance onset. Are there any analytical ways to connect the parameters L, k and m of the logistic equation with the parameters n, theta and alpha from the dynamical system? It would help to reduce the number of parameters/equations to keep the text more concise and easier to follow. In the model, the Hill coefficients are first introduced as free parameters, but are later set to a constant value for all cases. The same applies for gamma, kA and kB; how were these values determined? A quantitative assessment of the impact of parameter values should be provided. Collateral sensitivity enters into the model through the coupling constant beta, which is given as beta=gamma 2^ (-x) , where x is a value from the collateral sensitivity/resistance matrix in Fig. 6 . Values in the matrix are log2 transformed MIC-fold changes; hence, beta directly equals gamma times the MIC fold change. However, the reported values for CHL -POL and POL-CHL do not agree with this (given that gamma=0.1). Setting all coupling constants beta to 0 might be a useful null-model when comparing correlation between the observed and predicted MIC of drugs (Fig. 3) . Such a null model would be useful to assess how successful the theoretical predictions are.
It would help to emphasize that this model is phenomenological and it should be explained why the authors chose this model over well-established population genetics models for such evolution experiments. A population genetics model could provide deeper insight into the evolutionary dynamics, in particular the peculiar dynamics observed for POL ( Fig. 1e ): e.g. what is the beneficial mutation rate that would lead to such dynamics? The effect that POL resistance evolves perfectly reproducibly after exactly 7 days in this experiment is potentially interesting but deserves some explanation: is this plausible given the inherent stochasticity of evolutionary dynamics?
3. In the Discussion section, the authors argue: "From a clinical point of view, our finding is crucial because it suggests that the decreased efficacy of an antibiotic can be restored, even from a multi-drug resistant bacterial population, by adopting a time-modulated drug dosing strategy." This claim may be true for de novo developed resistance in mixed populations and less so for clinically troublesome multi-drug resistant bacteria. Already the text on page 11 of the manuscript indicates that reversibility is possible but in a very special regime of a mixed population (which is maintained due to antibiotic cycling). These claims of clinical rel evance should be supported by corresponding data or toned down.
4. In general, when stating and comparing quantities (e.g., k rates) errors and, where applicable, appropriate statistical tests of the claims should be reported. In order to maintain the flow of the text, the statistical tests used and the p-values could be reported in the supplement.
5. The cultures used in genome extractions were grown overnight in the absence of antibiotic. Was it verified that resistance occurrence in the population wa s not lowered (if associated with the fitness cost), e.g., by comparing the ratios of colony forming units on plates with and without antibiotic before and after overnight incubations?
6. In the morbidostat protocol that is used, what is the growth rate in the absence of the antibiotic? What is the relative growth inhibition given the dilution and antibiotic concentration adjustment protocol described in the Method section? Is the relative inhibition indeed identical for all used antibiotics? What is the average number of antibiotic concentration adjustments needed to achieve constant inhibition? Is this time comparable with the switching rate?
7. Some of the chosen antibiotics (kanamycin, ampicillin) are known to have a very steep dose-response curve, i.e. the growth rate as a function of antibiotic concentration has a very abrupt drop, which in turn makes it hard to control growth inhibition in a device like the morbidostat. How was this problem solved? Sample growth curves for the single antibiotic regime for all used antibiotics should be provided (i.e. Supp. Fig. 1b with real data).
8. Figure 1 suggests that the MIC of CHL and NIT increased roughly 16 fold over the course of 12 days. Data from the cited references (Toprak et al., Nature Genetics, 20 12) and (Chevereau et al., PLoS Biology, 2015) shows that the IC50 increased by a considerably larger factor for both drugs in similar experiments. It would be helpful to explain the (potential) origin of these discrepancies. Supplementary Figure 5 states that the original data is shown in Fig. 1 , which is not the case for RIF, AMP and TET. It would be important to provide the absolute increases in MIC for all drugs for cross-validation with existing literature.
9. Collateral sensitivity/resistance profiles were measured before (e.g. in the cited reference Imamovic and Sommer, Sci. Trans. Med. 2013 and in Oz et al., Mol Biol Evol, 2014) . It would be helpful to provide a scatter-plot comparing the measured values with the reference values. These previous studies established that resistance to aminoglycosides (e.g. KAN) renders strains very sensitive to many antibiotics of other classes; this is less clear in the data presented here and it would be helpful to comment on this.
Minor points: 1. In the second paragraph of the introduction, it is worth mentioning that keeping bacterial cultures in the exponentially growing regime is crucial to achieve a well-controlled physiological state.
2. If x and m in the logistic equation are given in the units of time (e.g., days) then values for k should be reported with units of inverse time which is not the case. If some normalization was used that renders values unit-less, this should be reported.
3. In the section "Evolution against single antibiotic ..." evolutionary patterns are divided into two categories according to the rapidness and length of lag phase: were the k and m values used as a classifier? If so, the threshold values should be reported. Fig. 3 should be done more quantitatively by reporting the corresponding correlation coefficients or other metrics. Also, figure 3 should be explained in a bit more detail; including a concise explanation why pairs of cycled drugs appear twice in inverse order would facilitate the understanding of this important figure. Also, why are these pairs sometimes very similar (e.g. NIT -CHL, CHL-NIT) and sometimes extremely different in these plots (KAN-POL, POL-KAN)? We indeed paid special attention to the possibility of cross resistance. For instance please refer to Supplementary Fig.6 , the cross resistance and collateral sensitivity profile. For example, tetracycline(TET)-resistant bacteria (top row) showed cross resistance to many other antibiotics (coloured as red), and most of drug resistant bacteria showed cross resistance to rifampicin (RIF, second rightmost column). For these reasons, we did not conduct any combinatorial experiments with TET/RIF except RIF-POL combination. We removed the sentence including the term and also reduced the reference to clinical cases to emphasise the bacterial evolution aspect of our study.
Comparison of the experimental results in
Discussion new bacterial resistance. This problem needs to be solved for this work to be of general utility.
We agree with the reviewer. Our result may suggest a key to suppress/delay/reverse drug resistance, but we also think we should be careful when translating our results to practical situations and further experiments are still required for our work to be of general utility. Thus, we added following sentence in the Discussion section:
Line 370-374:
Our findings indicate that the decreased efficacy of an antibiotic can be restored by modulating antibiotic stress however care must be taken when translating these results to clinical settings given that our experiments here considered de novo chromosomal mutations only. Further experiments, such as evolution experiments with plasmid-mediated antibiotic resistance, would be required to elucidate the feasibility of resistance suppression by antibiotic cycling in more practical situations.
Methods: scientific names should be italic

Methods: give a reference for lysogeny broth composition
Methods: E. coli should have a space and be in italic Operation … growths?
Corrected.
MIC measurements: define more carefully what you mean by gradient of concentrations. Do you have gradients in the plates? If so, how do your MIC values relate to standard measurements?
We are sorry for the confusing description of our method. This method is similar to the broth micro-dilution method, but uses a set of agar plates with varying antibiotic concentrations (√ -fold serial dilution). We modified the sentence as follows:
Line 456-457: The MIC of samples collected during evolution experiments was measured by growing the samples on a set of LB agar plates with varying antibiotic concentrations.
Visible colonies -with the pin applicator do you see individual colonies or are you simply scoring a mass of growth? If the latter, is there concern about the effect of innoculum size? If you actually see colonies, how many were there at sub-MIC concentrations?
We saw individual colonies after overnight incubation. With our 384 pin replicator, approximately 0.1 ul of cell culture was applied on the plate. If bacteria did not grow on a spot, the culture was dried out and there was no trace of bacteria on the spot. MIC concentration was defined as the lowest antibiotic concentration that bacterial growth did not occur. Below is a picture of the agar MIC measurement for reference.
Bottom of page 15. Use of the term resistance will be seen by some readers as careless. This is because resistance is defined clinically as isolates whose MIC exceeds an empirical breakpoint. An isolate is either resistant or it is not. The term susceptibility (or decrease in susceptibility) is used to be clear. Biochemists tend to ignor this distinction.
We used the terms based on the definition commonly used in the field of bacterial evolution, in which a wild type strain was defined as a susceptible strain. We added our definition in the "MIC measurement" of Method section to clarify this.
Line 454-455: First, we defined a wild-type MG1655 strain as a susceptible strain. Resistant strains were defined as any (evolved) bacterial samples whose MIC exceeds that of the wildtype strain.
Mutant frequency -do you mean mutstion frequency? If this method is not accurate, as the authors state, then the section should be revised to stress what you really measured. The current phrasing is not professional.
We apologise for the confusing term. We changed the term as "allele frequency", a fraction of mutants in a population that carry particular mutations in a gene that confer resistance to an antibiotic (in the current case, polymyxin B), which was calculated from fluorescent signal intensities at a position of Sanger sequencing data
The main result of this study is that certain combinations of antibiotics can reverse multidrug resistance. This is a potentially interesting observation that could, in principle, help in the design of rational drug usage strategies to fight clinically relevant pathogens. However, this observation has been previously reported using different bacteria and drug combinations and therefore, although methodologically sound, I believe this study is not conceptually novel.
We thank the reviewer for the supportive comments. The reversal of evolved antibiotic resistance was indeed one of the main results in our study. We are also aware that there are several publications reporting such evolutionary behaviour (e.g. 10.1073/pnas.1320886110, 10.1016/j.ijantimicag.2012.02.007 and 10.1038/nchembio.2176). However, we think that our theoretical model will be is the main novel contribution to the field because of the reasons explained below, and the reversing experiments was conducted to demonstrate the predictive power of our multi-drug evolution model.
The reasons why we think our study is novel are:
(1) Existing math model studies for bacterial antibiotic resistance evolution are designed for / based on particular drugs or drug combinations. .
The continuous culture device constructed by the authors is very interesting, as it allows implementation of feedback controllers that dynamically manipulate the environmental conditions from real-time estimates of bacterial density. Previous studies have focused on implementing serial dilution protocols with daily transfers, and therefore imposing a temporal structure characterised by growth-dilution cycles, but also limiting the switching rate to periods longer than one day. Surprisingly, despite the possibilities offered by their experimental system, the authors choose to implement periodic cycles with daily switches because "shorter intervals tended to delay the development of the antibiotic resistance" (page 5). This is a strange reason to ignore rapid switching rates, in particular given that the main goal of the study is "to suppress the development of drug resistant mutants" (page 2).
As the reviewer mentioned here, we constructed the device to overcome the limitations of the conventional serial dilution method, especially to keep bacterial cultures in the exponentially growing regime which is crucial to achieve a wellcontrolled physiological state. In principle, it is possible to switch antibiotics with shorter periods (e.g. every 6 hours). However, faster switching could result in mixing of two antibiotics. As our main focus in this study is the effect of temporally segregated antibiotic stresses where we limit the minimum switching rate to be one day to avoid mixing of antibiotics. We are currently investigating the effect of mixed drug stresses using the same system, which we hope to report these results soon. Indeed, the fitness cost is a key factor in the modelling of bacterial drug resistance evolution as widely recognised from experimental studies (e.g. 10.1038/nrmicro2319), and it is also implicitly integrated in our model. An increased fitness cost of multidrug resistance was introduced as negative feedback loop ---If a (sub)population develops resistance to drug A, then it suppresses the development of drug B resistance. The higher the drug A-resistance level is, the more the drug B-resistance is supressed. This construction of the model effectively means that the pathway to multi-drug resistance tends to be inhibited (due a lower fitness).
and therefore it's not surprising that multidrug resistance can be reversed when only one antibiotic is deployed.
It is indeed not surprising that multi-drug resistance can be reversed from a theoretical model point of view. This is why we conducted the reversing experiments. However, what was surprising to us was that drug resistance of a bacterial population can be reversed even after 24 day exposure to antibiotic cycling (Fig.4a , although this is a case of single-drug resistance). In contrast, a population with 12 day exposure to single antibiotic ( Supplementary Fig.8c ) did not show any reversal. A possible explanation for these different outcomes was that antibiotic cycling prevented selective sweeps to happen. We also found that this genetic/phenotypic heterogeneity was a key for the reversibility of drug resistance. To our best knowledge, this heterogeneous population aspect was not recognised in the previous antibiotic cycling research (experimental/theoretical), and hence it is one of our contributions to the field. To reflect these points, we modified the text as follows Line 298-305: One of the important implications in the model is that the evolution of bacterial drug resistance can be viewed as a dynamical system because the model proposed here is a simple deterministic system. Such dynamical systems view of biological systems was previously proposed in the context of stem cell differentiation and drug resistance evolution of caner cells 44, 45 . The samples for MIC assay and genome extraction were prepared in the same method, overnight incubation in LB. Hence, all the MIC and genome data in the paper all are corresponding.
In addition, we tested if the resistance level changes during overnight incubation in the presence or absence of antibiotics. We used the resistant samples evolved under single antibiotic conditions and compared MIC values after incubated overnight with and without antibiotics. The MIC values were same regardless of antibiotic exposures during the overnight incubation (see Supplementary Fig. 11 ).
Furthermore, we measured colony forming unit of a resistant strain to see if the resistance level changes during overnight incubation without antibiotics. We used the final day sample of POL and CHL cycling (Fig 4a, 24 th day) which had acquired only POL resistance through the cycling experiment. The frequency of survivors was compared between a frozen stock and overnight culture of the stock without antibiotics. Again, no significant difference was observed between two conditions (Supplementary Fig. 12 ).
These results show that the overnight incubation before MIC measurement or genome extraction did not affect to the MIC levels of samples.
Above explanation was added in the Method section (Line 487-495).
My main concern about this manuscript, however, is that the authors ignore a considerable body of literature relevant to the antibiotic cycling problem and yet they state in the introduction that "systematic investigations into how a bacterial population develops resistance to multiple cycling antibiotics have yet to be done". Indeed, this is a very difficult problem and one that needs more attention from scientific and medical communities and, although I think this study could be a contribution in the search for rational antibiotic deployment strategies
We feel there is a misunderstanding here regarding the term "systematic". With "systematic investigations", we do not mean investigations using theoretical models, but "exhaustive experimental investigation into bacterial evolutionary patterns by testing a number of antibiotic cycling combinations", which we think it is true, to our best knowledge. We apologise for using a confusing term and now it is corrected as follows:
Line 45-47: However, an exhaustive experimental investigation of effective antibiotic cycling combinations for suppressing the emergence of bacterial drug resistance is yet to be conducted.
I also believe its imperative that the authors put their findings in the context of previously published studies.
In addition to the corrections mentioned above, we expanded the introduction and discussion sections to describe our study in the context of previous studies. Please refer to Line 351-377 for details. We thank the reviewer for supportive comments and also for understanding the novelty of our work. We performed additional experiments and revised the manuscript according to the comments. We made a section ("Evolutionary patterns and possible mechanisms of drug resistance suppression") to explain the observed patterns. Simply put, we think this would be due to the different culture methods. The previous study by Kim et al. used the serial transfer method. In general, bacterial evolution would be slower with this method as the bacteria need to adapt to the log and stationary phase conditions during overnight culture, while the log phase is always maintained in morbidostat, which may have led to various evolutionary patterns (e.g. rapid evolution with KAN or NAL resistance, slow evolution with CHL or NIT resistance). Under antibiotic cycling conditions, evolution with serial transfer method would be even slower, and hence it showed monotonic increases consistently. In contrast, evolution in morbidostat would be diverse due to the combination of various single evolution patterns.
Please refer to the section (page 6) for more details.
Also, the data in Fig. 1c 
Overall, it would greatly help to explain the plausibility of these results in the framework of basic population genetics (see below).
Please refer to the new section ("Evolutionary patterns and possible mechanisms of drug resistance suppression"), which we discuss the unique evolutionary patterns we observed, i.e. (1) the delayed POL resistance evolutionary trajectory, (2) suppression of POL resistance in KAN-POL cycling, and (3) suppression of CHL resistance in CHL-POL cycling. We tried to explain the behaviour from population genetics as well as population dynamics point of view.
The theoretical model described in the Supplement contains parameters that are closely related to the parameters of the logistic equation used to quantify the abruptness of the antibiotic resistance onset. Are there any analytical ways to connect the parameters L, k and m of the logistic equation with the parameters n, theta and alpha from the dynamical system? It would help to reduce the number of parameters/equations to keep the text more concise and easier to follow.
Yes, L, k, and m of the logistic equation correspond to / , , and , respectively. However, it should be noted that they correspond qualitatively, not quantitatively. We considered using logistic parameters for the model, but discarded the idea because of two reasons:
(1) m and do not correspond directly because m is the mid-point of the curve while is the start point. They can be in principle converted using the definition of theta as = − 
Collateral sensitivity enters into the model through the coupling constant beta, which is given as beta=gamma 2^(-x), where x is a value from the collateral sensitivity/resistance matrix in Fig. 6. Values in the matrix are log2 transformed MIC-fold changes; hence, beta directly equals gamma times the MIC fold change. However, the reported values for CHL-POL and POL-CHL do not agree with this (given that gamma=0.1).
Please note that negated value (-x) was used to calculate beta. Thus, beta is gamma times the reciprocal of the MIC fold change. 
= . ~ .
We also noticed that the values in the matrix was rounded, but we used the original values for calculation (Line 252-255 in the Supplementary Information), hence they were not completely in agreement. We apologise for the error and provided the original data as Supplementary Data 2. (Fig. 3) . Such a null model would be useful to assess how successful the theoretical predictions are.
Setting all coupling constants beta to 0 might be a useful null-model when comparing correlation between the observed and predicted MIC of drugs
We added scatter plots (similar to Fig.3 ) comparing a null model (with = ) with experimental data as Supplementary Fig. 10 . Such null model has no interaction between antibiotic resistance and hence resistance levels to both antibiotics approach to the maximum. As a result, values were 0.03 and 0.20 for the two drug resistances, respectively, while 0.44 and 0.64 with our model. We modified the manuscript to reflect this. Please see Line 257-263.
It would help to emphasize that this model is phenomenological and it should be explained why the authors chose this model over well-established population genetics models for such evolution experiments
We agree with the reviewer. Our model presented here simulates bacterial evolution at the phenotypic level and no underlying genetic dynamics was incorporated. Although population genetics model, such as 10.1126/science.1122469 and 10.1371/journal.pbio.1002299 can be used to model the observed evolutionary behaviour, we here used the phenotypic evolutionary model because of reproducible phenotypic evolutionary patterns despite diverse underlying genotypic mutations in morbidostat, as previously observed by Toprak and colleagues. Similar evolutionary patterns were also observed in the bacterial ethanol stress adaptation by some of us, supported by a theoretical model. We modified the text as follows:
Line 204-210: It should be noted that we employed a phenomenological model rather than commonly adopted population genetics models 8,33,34 . Previous studies revealed that, despite diverse underlying genetic alterations, bacterial evolution for stress resistance can exhibit remarkably similar trajectories 7,8,35-37 . Additionally, from a prediction point of view, it is helpful if a model is based on experimental parameters that can be measured relatively easily. Thus, we here developed a theoretical model relying only on relative MIC levels.
A population genetics model could provide deeper insight into the evolutionary dynamics, in particular the peculiar dynamics observed for POL (Fig. 1e): e.g. what is the beneficial mutation rate that would lead to such dynamics? The effect that POL resistance evolves perfectly reproducibly after exactly 7 days in this experiment is potentially interesting but deserves some explanation: is this plausible given the inherent stochasticity of evolutionary dynamics?
Although we do not have population genetics models to explain the observed phenomena at the moment, we are speculating that this reproducible dynamics of POL resistance evolution might be partly because of non-genetic drug resistance We have corrected the corresponding part of the text to tone down the claim as follows:
Line 370-374: Our findings indicate that the decreased efficacy of an antibiotic can be restored by modulating antibiotic stress however care must be taken when translating these results to clinical settings given that our experiments here considered de novo chromosomal mutations only. Further experiments, such as evolution experiments with plasmid-mediated antibiotic resistance, would be required to elucidate the feasibility of resistance suppression by antibiotic cycling in more practical situations. Fig. 5b . Pvalues were added in the main text and Supplementary Fig.4 (comparison of cycling  rates) . Details of the statistical measures were added in the Method section ("Morbidostat data analysis" section).
In general, when stating and comparing quantities (e.g., k rates) errors and, where applicable, appropriate statistical tests of the claims should be reported. In order to maintain the flow of the text, the statistical tests used and the p-values could be reported in the supplement.
We added SEM values for k rates in the main text and in the Supplementary
The cultures used in genome extractions were grown overnight in the absence of antibiotic. Was it verified that resistance occurrence in the population was not lowered (if associated with the fitness cost), e.g., by comparing the ratios of colony forming units on plates with and without antibiotic before and after overnight incubations?
The samples for MIC assay and genome extraction were prepared in the same method, overnight incubation in LB. Hence, all the MIC and genome data in the paper are corresponding.
We also performed additional experiments and measured the colony forming unit of a resistant strain to see if the resistance level changes during overnight incubation without antibiotics. We used the final day sample of POL and CHL cycling (Fig 4a, 24 th day) which had acquired only POL resistance through the cycling experiment. The frequency of the survivors was compared between a frozen stock and overnight culture of the stock grown without antibiotics. However, no significant difference was observed between two conditions (Supplementary Fig. 12) .
In addition, we tested if the resistance level changes during overnight incubation in the presence or absence of antibiotics. We used the resistant samples evolved under single antibiotic conditions and conducted two overnight incubations, with and without antibiotics. Again, the MIC values between these cases were quite close regardless of antibiotic exposures during the overnight incubation. The wild-type MIC level was used for the overnight incubation. These results show that the overnight incubation before MIC measurement or genome extraction did not affect to the MIC levels of samples ( Supplementary Fig. 11 ).
Above explanation was added in the Method section (Line 487-495).
In the morbidostat protocol that is used, what is the growth rate in the absence of the antibiotic?
The growth rate without antibiotics was ~1.0(/h), although it was constantly fluctuating due to measurement noise. Please see Supplementary Fig. 14 .
What is the relative growth inhibition given the dilution and antibiotic concentration adjustment protocol described in the Method section? Is the relative inhibition indeed identical for all used antibiotics?
It was commonly observed that the growth rate fell between 0.2-0.4 after antibiotics were added (Supplementary Fig. 14) . As the reviewer mentioned below, some antibiotics (e.g. KAN, NAL, AMP) indeed caused stronger inhibition than other antibiotics, which decreased the growth rate to below zero. However, the rate came back to 0.2-0.4 after the drug concentration in the cell culture was diluted by LB without antibiotics.
What is the average number of antibiotic concentration adjustments needed to achieve constant inhibition? Is this time comparable with the switching rate?
The average number of antibiotic adjustments depended on the antibiotics used. In general, the antibiotics with larger (e.g. KAN) required more adjustments than those with smaller (e.g. CHL). Please refer to Supplementary Fig. 15 . We did not see any correlation between the number of adjustments and switching rate.
Some of the chosen antibiotics (kanamycin, ampicillin) are known to have a very steep dose-response curve, i.e. the growth rate as a function of antibiotic concentration has a very abrupt drop, which in turn makes it hard to control growth inhibition in a device like the morbidostat. How was this problem solved?
This is a reason why we used a higher OD threshold (OD=0.4) than that of the original morbidostat experiment (OD=0.15). If the threshold is low, the entire bacterial population could be killed by an antibiotic before the antibiotic concentration was diluted by the growth medium (LB), and the bacterial growth did not recover. Thus, we hypothesised that a proportion of bacteria would survive if the cell density is relatively high. Some antibiotics (e.g. KAN, AMP, NAL) indeed showed strong and abrupt growth inhibition as shown in Supplementary Fig.14 . However, with a higher OD threshold, we observed the growth recovery after several hours of no growth period at very low OD (below the sensitivity of optical sensor), and were able to obtain the reproducible evolutionary patterns in the cases tested here.
We inserted following text to mention about this in the manuscript:
Line 433-435: Note that we used a higher OD threshold than the previous study (OD THR =0.15)
7
. This is because some antibiotics caused strong growth inhibitions than the other antibiotics ( Supplementary Fig. 14) , which make the control of growth inhibition difficult in morbidostat.
Sample growth curves for the single antibiotic regime for all used antibiotics should be provided (i.e. Supp. Fig. 1b with real data) .
We added the data as Supplementary Fig. 14. 8. Figure 1 suggests that the MIC of CHL and NIT increased roughly 16 fold over the course of 12 days. Data from the cited references (Toprak et al., Nature Genetics, 2012) and (Chevereau et al., PLoS Biology, 2015) shows that the IC50 increased by a considerably larger factor for both drugs in similar experiments. It would be helpful to explain the (potential) origin of these discrepancies.
This would be because the total duration of antibiotics exposure was different from the previous studies. In our experiments, we exposed the bacteria to each antibiotic only for 12 days which is almost half the period compared to the other two papers. We compared the resistance levels at day 12 in the table below. For CHL resistance in our experiment, log2(MIC fold change) was 4.64 (Fig.1d) The original data was added as Supplementary Fig.5b. Imamovic and Sommer, Sci. Trans. Med. 2013 and in Oz et al., Mol Biol Evol, 2014) 
Collateral sensitivity/resistance profiles were measured before (e.g. in the cited reference
. It would be helpful to provide a scatter-plot comparing the measured values with the reference values.
We added a scatter-plot comparing the log2-transformed relative MICs to the parent strain in Supplementary Fig. 13 . We compared the four datasets here, one from Imamovic et al., two from Oz et al. (strong selection and mild selection) , and ours. Generally, our dataset displayed agreements with other datasets.
These previous studies established that resistance to aminoglycosides (e.g. KAN) renders strains very sensitive to many antibiotics of other classes; this is less clear in the data presented here and it would be helpful to comment on this.
We also observed collateral sensitivities of KAN-resistant strain to other antibiotics (POL, CHL, NAL). However, it was not as evident as those of POL-resistant strain. We think this less clear KAN collateral sensitivity in our case was due to different
Toprak et al. Chevereau et al.
Our result Fig. 13 ) 26, 32 , some collateral sensitivity profiles (e.g. KAN) were less evident compared to previous cases. This may be due to different selection strengths during evolution between previous and our cases because the collateral sensitivity/cross resistance profile is known to be dependent on the selection strength 32 .
Corrected as follows:
Line 56-59: The use of the automated cell culture system was important not only in delivering programmable dosing, but the morbidostat system enabled maintenance of bacterial populations in exponential growth phase. Thus the platform was expected to provide good phenotypic reproducibility between parallel experiments 14 whilst enabling genetically diverse populations to co-exist 30,31 .
If x and m in the logistic equation are given in the units of time (e.g., days) then values for k should be reported with units of inverse time which is not the case. If some normalization was used that renders values unit-less, this should be reported.
"day -1 " was added as the unit for the parameter k.
In the section "Evolution against single antibiotic ..." evolutionary patterns are divided into two categories according to the rapidness and length of lag phase: were the k and m values used as a classifier? If so, the threshold values should be reported.
We used k and (the length of lag phase) as classifiers with threshold = =2.5. was calculated as a time when the resistance level exceeds 0.1 using logistic function and the parameter values k and m and L (maximum value of the curve) as
. We added calculated values in Supplementary Fig.S5b . The equation to calculate is added in Methods (Line 476-477). Fig. 3 should be done more quantitatively by reporting the corresponding correlation coefficients or other metrics.
Comparison of the experimental results in
cycling (KAN as drug #1 and POL as drug #2) was mapped on the x axis because only KAN resistance was developed while POL resistance was completely suppressed. In general, the results can be categorised into two groups, i.e. the single and multi-drug resistant states, as observed above. The former cases (e.g. KAN-POL) were plotted either on one of the axes, while the latter ones (e.g. NAL-KAN) were in the upper right part of the plot. To illustrate the predictability of the theoretical model, the normalised predicted MIC values were plotted against the normalised observed MIC values ( Fig.3c and d) . Overall, the model predictions showed good correlations with the experimental results ( = . and . , respectively).
We added these details in Fig.3 caption, Line 287-296.
Morbidostat data analysis: Is the expression for the growth rate missing a logarithmic transformation of OD values? If the written equation was actually used, please report the regime in which such linear approximation is valid.
We apologise for the typo. The equation is now corrected as = � � / × . Corrected. We also checked the manuscript for other grammatical errors very carefully.
Supplementary
REVIEWERS' COMMENTS:
Reviewer #1 (Remarks to the Author):
GENERAL COMMENTS I believe this will be an important paper that deserves to be written very carefully. Below I have made a few suggestions that may improve comprehension speed and author credibility. These comments are not comprehensive. My major comment concerns the Discussion (marked with an asterisk below). It should be rewritten.
SPECIFIC COMMENTS
Line 26 sentence regarding cycling. This has been tested clinically with mixed results and is not a general solution to the problem (squeezing the balloon). Readers intere sted in the present work will know that, and they will want a bit more comment and reference citations to establish the knowledge base of the present authors regarding the clinical situation. This is addressed somewhat at line 38, but that seems a bit late. give this information, indicate that here as described below -don't make the reader think that you left a big hole in the study. Line 176. Please explain why heteroresistance is not in the category of genetic mutation. By genetic mutation I assume you mean DNA-based mutation. The logic and writing of this passage needs to be more careful. You may be able to solve some of the problem by using "new spontaneous mutation". Are there mutations in E. coli that are not genetic, that is, DNA based? Line 180. Low and high drug concentrations. To this point I have not seen any information on drug concentration. Thus, the meaning is unclear. You have that information in the methods, but it breaks up the flow to have to flip to methods to understand the general nature of the experiment. Moreover, this important point is hidden in a section of the Methods. Line 194. Loss of resistance. My initial comment was that this seems like an important point and the data should be in the main text, not the supplementary material. Then later I find a section dealing with this topic. The solution is a "discussed below" statement. This example raises a general problem in the manuscript: putting the cart before the horse. I suggest that the entire manuscript be carefully reviewed so other examples can be corrected. Line 309. Please add a reference for last resort. Line 358. Delete exhaustive. This is a red flag to the reader. In general, avoid valuejudgment statements about your own work. Let the reader draw this conclusion. Discussion. This section adds very little to the paper and would be better titled "Summary". A Discussion would delete the summary material and focus on 1) how your results differ from failed clinical and animal studies, 2) how your studies differ from pharmacodynamic models (see Firsov and Zinner) and how the two can be combined to be closer to reality, and 3) how your studies can be extended to animal systems (examples are tissue -cage studies in which cycling can be performed along with sampling of bacterial populations and drug concentration [see Cui 2006 J. Inf Disease] ). Such a treatment will excite experts in other aspects of resistance to use your findings, because they will not have to think so hard to get started. *Line 437. The drug concentration information is hidden in the Methods. This very simple statement should be early in the text, because concentration is extremely important for the entire work. For most readers, using concentrations at 10-times MIC constitutes extreme stress, in most cases lethal stress. More comment on concentration is required. In particular, it would be good to state (in the Discussion) that while you measured MIC, it is likely that the concentrations you used were actually lethal (for the lethal drugs) and that further work is needed to assess the importance of killing (this will make it clear that you understand the difference between assays for blocking growth and assay for survival [killing] ). You may also want to mention that 10x MIC is likely to place concentrations high in the mutant selection window (depending on the drug), which will limit the resistance alleles you expect to be selectively enriched (such a statement will make it clear that you understand the importance of concentration; a citation may be a review in Clin Inf Dis (2007) 44: 681 -688 by Drlica and Zhao).
Reviewer #2 (Remarks to the Author):
The revised manuscript clarifies many of the issues raised by the reviewers and implemented the suggestions of my previous report in a fully satisfactory manner.
Reviewer #3 (Remarks to the Author):
In the revised version, the authors have carried out additional experiments and analysis and improved the text of the manuscript. They have addressed virtually all my concerns adequately. I still have doubts about choosing the presented phenomenological model over established population genetics models, but at least this is clearly stated and the analysis of the former model appears sound. I also appreciate the addition of statistical measures of significance and appropriate tests. Overall, I recommend the manuscript for publication.
A minor language point: I would try to think of a new term for the time needed before the onset of resistance (currently "lag phase"). The reason for that is the newly added explanation of the discrepancies between previous evolution experiments with serial transfer methods, where stationary phase is the main speculative reason for the observed disagreements (although "lag phase" is not referred to directly).
Responses to the reviewer comments:
We thank the reviewers for detailed suggestions to our manuscript. We have answered all the comments below. As a result, we feel our manuscript was greatly improved. We added another sentence to include a detailed explanation of the morbidostat and the drug concentration. Please note that the morbidostat system tries to maintain the mutant selection window. Namely, when the growth medium containing 10xMIC antibiotic is administered to a bacterial culture, the antibiotic will be diluted 1/12 times. As described below, antibiotic is added at least a few times and thus the antibiotic concentration in the culture will be above MIC, but much lower than 10xMIC (cf. Supplementary Fig.14) . Please also note that the paragraph was moved to Results section.
L 71-79:
In the morbidostat, the antibiotic concentration was automatically controlled by a custom algorithm 7 ; when a bacterial culture reaches a certain density, one mL of a growth medium containing an antibiotic was administered into twelve mL of a bacterial culture, while a medium containing no antibiotic was added at low cell density (Supplementary Methods). The antibiotic concentration in the administered growth medium was at least ten times higher than the minimum inhibitory concentration (MIC) of a wild-type strain. Typically, antibiotics were added at least a few times once the cell density exceeds a threshold level, and thus the antibiotic concentration was increased to the range of drug concentrations that select for drugresistant mutants (so-called "mutant-selection window" 33 ). Yes, by isogenic, we meant the strain originated from a single colony of E.coli MG1655 strain. We added this explanation in the Method as follows: L 367-369: Escherichia coli strain MG1655 was purchased from DSMZ (Germany) and streaked to single colonies. One single colony was selected and used throughout this study. We amended the sentence to emphasise that the chosen antibiotics to have different targets, and also changed the word "avoid" to "minimise" as weak cross resistances were commonly observed (Fig. 2) . L 89-91: Antibiotics were chosen from different classes so that they have different targets (Table 1) Regarding sequence analysis, we saw only one mutation in the efflux systems (marR gene in CHL and NIT cycling), although a few mutations in the upstream of mdfA (a multi-drug efflux system) were observed. Thus, we think the effect of multi-drug resistance by efflux pump mutations are negligible. We added a pointer to the later section as suggested: L 198-200: The latter case of CHL-POL cycling, in which CHL resistance was completely suppressed, can be explained by the reversible nature of CHL resistance (which was also observed with POL resistance, as described below).
